CO2022014490A2 - Compuestos inhibidores de phd, composiciones y uso - Google Patents
Compuestos inhibidores de phd, composiciones y usoInfo
- Publication number
- CO2022014490A2 CO2022014490A2 CONC2022/0014490A CO2022014490A CO2022014490A2 CO 2022014490 A2 CO2022014490 A2 CO 2022014490A2 CO 2022014490 A CO2022014490 A CO 2022014490A CO 2022014490 A2 CO2022014490 A2 CO 2022014490A2
- Authority
- CO
- Colombia
- Prior art keywords
- disease
- pulmonary
- acute
- heart disease
- compositions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 1
- 208000007788 Acute Liver Failure Diseases 0.000 abstract 1
- 206010000804 Acute hepatic failure Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010019669 Hepatic fibrosis and cirrhosis Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000033626 Renal failure acute Diseases 0.000 abstract 1
- 201000011040 acute kidney failure Diseases 0.000 abstract 1
- 231100000836 acute liver failure Toxicity 0.000 abstract 1
- 206010069351 acute lung injury Diseases 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 208000018578 heart valve disease Diseases 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992585P | 2020-03-20 | 2020-03-20 | |
| PCT/US2021/023219 WO2021188936A1 (en) | 2020-03-20 | 2021-03-19 | Phd inhibitor compounds, compositions, and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022014490A2 true CO2022014490A2 (es) | 2022-10-21 |
Family
ID=75639962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0014490A CO2022014490A2 (es) | 2020-03-20 | 2022-10-12 | Compuestos inhibidores de phd, composiciones y uso |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230227426A1 (https=) |
| EP (1) | EP4121425A1 (https=) |
| JP (2) | JP7768890B2 (https=) |
| KR (1) | KR20220156889A (https=) |
| CN (2) | CN119823097A (https=) |
| AR (1) | AR121618A1 (https=) |
| AU (1) | AU2021239378A1 (https=) |
| BR (1) | BR112022018877A2 (https=) |
| CA (1) | CA3176140A1 (https=) |
| CO (1) | CO2022014490A2 (https=) |
| IL (1) | IL296631A (https=) |
| MX (1) | MX2022011123A (https=) |
| TW (1) | TW202140443A (https=) |
| WO (1) | WO2021188936A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11713298B2 (en) | 2018-05-09 | 2023-08-01 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| WO2021117767A1 (ja) | 2019-12-10 | 2021-06-17 | 田辺三菱製薬株式会社 | 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法 |
| CN115991698B (zh) * | 2022-11-03 | 2024-03-29 | 广东中科药物研究有限公司 | 一种杂环化合物及其制备方法与应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| DE102006050515A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung |
| CA2894399A1 (en) | 2012-12-06 | 2014-06-12 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| EA031647B1 (ru) | 2013-03-29 | 2019-02-28 | Такеда Фармасьютикал Компани Лимитед | 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd |
-
2021
- 2021-03-19 AR ARP210100691A patent/AR121618A1/es unknown
- 2021-03-19 MX MX2022011123A patent/MX2022011123A/es unknown
- 2021-03-19 AU AU2021239378A patent/AU2021239378A1/en active Pending
- 2021-03-19 WO PCT/US2021/023219 patent/WO2021188936A1/en not_active Ceased
- 2021-03-19 TW TW110109982A patent/TW202140443A/zh unknown
- 2021-03-19 JP JP2022556170A patent/JP7768890B2/ja active Active
- 2021-03-19 CN CN202510216379.8A patent/CN119823097A/zh active Pending
- 2021-03-19 CA CA3176140A patent/CA3176140A1/en active Pending
- 2021-03-19 EP EP21720873.5A patent/EP4121425A1/en active Pending
- 2021-03-19 US US17/906,650 patent/US20230227426A1/en active Pending
- 2021-03-19 KR KR1020227036362A patent/KR20220156889A/ko active Pending
- 2021-03-19 IL IL296631A patent/IL296631A/en unknown
- 2021-03-19 CN CN202180034124.XA patent/CN115551845B/zh active Active
- 2021-03-19 BR BR112022018877A patent/BR112022018877A2/pt unknown
-
2022
- 2022-10-12 CO CONC2022/0014490A patent/CO2022014490A2/es unknown
-
2025
- 2025-10-30 JP JP2025183157A patent/JP2026021443A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022011123A (es) | 2023-01-04 |
| AU2021239378A1 (en) | 2022-11-17 |
| TW202140443A (zh) | 2021-11-01 |
| CN115551845A (zh) | 2022-12-30 |
| CA3176140A1 (en) | 2021-09-23 |
| US20230227426A1 (en) | 2023-07-20 |
| EP4121425A1 (en) | 2023-01-25 |
| JP2023518953A (ja) | 2023-05-09 |
| AR121618A1 (es) | 2022-06-22 |
| WO2021188936A1 (en) | 2021-09-23 |
| CN119823097A (zh) | 2025-04-15 |
| KR20220156889A (ko) | 2022-11-28 |
| CN115551845B (zh) | 2025-02-28 |
| JP7768890B2 (ja) | 2025-11-12 |
| JP2026021443A (ja) | 2026-02-10 |
| IL296631A (en) | 2022-11-01 |
| BR112022018877A2 (pt) | 2022-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022014490A2 (es) | Compuestos inhibidores de phd, composiciones y uso | |
| CO2022014587A2 (es) | Compuestos inhibidores de phd, composiciones y uso | |
| JP2017526636A5 (https=) | ||
| AR130425A1 (es) | Inhibidores de kras(g12d) | |
| CY1122860T1 (el) | 3,5-διαμινο-6-χλωρο-ν-(ν-(4-(4-(2-(εξυλ(2,3,4,5,6-πενταϋδροξυεξυλ)αμινο)αιθοξυ)φαινυλ)βουτυλ)καρβαμιμιδοϋλ)πυραζινο-2-καρβοξαμιδιο | |
| AR121626A1 (es) | Compuestos inhibidores de phd, composiciones y métodos de uso | |
| PE20210046A1 (es) | Agonistas de fenilpirrolidinona del receptor 2 de formil peptido | |
| CU20100118A7 (es) | Compuestos orgánicos | |
| CL2023000532A1 (es) | Derivado de nitrilo que actúa como inhibidor de la dipeptidil peptidasa 1 y su uso | |
| AR111178A1 (es) | Inhibidor de la quinasa reguladora de la señal de apoptosis | |
| JP2009544602A5 (https=) | ||
| MX2009001659A (es) | Compuestos de 2,5-dihidroxibenceno para el tratamiento de rosacea. | |
| NI200800008A (es) | Métodos para la neuroprotección | |
| AR073031A1 (es) | Composiciones terapeuticas que contienen macitentan | |
| MX2025007935A (es) | Nuevos inhibidores reversibles de dpp1 y usos de estos | |
| JP2008546770A5 (https=) | ||
| CL2023002616A1 (es) | Inhibidores del sarcómero cardíaco | |
| RU2005105564A (ru) | Производные бензимидазола и их применение в качестве пролекарств ингибиторов протонного насоса | |
| AR134363A1 (es) | Derivado de ácido 2-(pirrolidina-3-il)acético sustituido, método de preparación y uso de este | |
| DOP2025000101A (es) | Derivados de benzimidazol cíclico como inhibidores de cgas | |
| EA200100906A1 (ru) | Композиция контролируемого высвобождения для лечения copd хронического обструктивного заболевания легких | |
| CO2022015205A2 (es) | Procesos para la preparación de un inhibidor de cinasa | |
| AR123243A1 (es) | Compuestos inhibidores del phd, composiciones y métodos de uso | |
| MX2024009270A (es) | Compuestos bloqueadores de canales de sodio epiteliales sustituidos con bifenilo | |
| JP2020503267A5 (https=) |